Human IL-1a ELISA

IL-1a and IL-1ß are prominent agonists mediating inflammatory and immunomodulatory effects. Both are produced by macrophages, monocytes and dendritic cells. They are important part of the inflammatory response against infection. They increase the expression of adhesion factors on endothelial cells to enable transmigration of leukocytes to sites of infection. IL-1a is a pleiotropic cytokine involved in various immune responses, inflammatory processes, and hematopoiesis. It is produced by many cell types but is only secreted by monocytes and macrophages.

A. Benefits:

  • Cost-effective analysis - High Quality with the most competitive price.

  • Efficient and flexible - Multiple samples can be analyzed simultaneously with a flexible number of assay wells.

  • Specific- A pair of highly selective antibodies specifically against human IL-1a.

  • Simple procedure All in one system with a pre-coated 96-well plate.

B. Principle of the technology

IL-1a ELISA is based on the principle of a solid phase enzyme-linked immunosorbent assay. The assay utilizes rabbit anti-human IL-1a for immobilization on the microtiter wells and biotinated rabbit anti-human IL-1a antibodies along with streptavidin conjugated to horseradish peroxidase (HRP) for detection. The test sample is allowed to react simultaneously with the two antibodies, resulting in the IL-1a molecules being sandwiched between the solid phase and enzyme-linked antibodies. After incubation, the wells are washed to remove unbound-labeled antibodies. A HRP substrate, TMB, is added to result in the development of a blue color. The color development is then stopped with the addition of Stop Solution changing the color to yellow. The concentration of IL-1a is directly proportional to the color intensity of the test sample. Absorbance is measured spectrophotometrically at 450 nm.

Figure 1
Diagram

Figure 2
Figure 2

 

 Product Size Cat. Price
Human IL-1a ELISA 96 EA-0503 $319
  • Human IL-1a ELISA User Manual (PDF)
Related information:
©2007-2008 Signosis, Inc.